Are you or your loved ones suffering from glioma?

You may be eligible to participate in a glioma clinical trial.

Are you or your loved ones suffering from glioma? You may be eligible to participate in a glioma clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

H3 K27M-mutant High-Grade Glioma
NCT03295396 | Phase 2 | Interventional
What you may receive

Study related treatment at no cost

Oncoceutics Inc
Sponsored by
Oncoceutics Inc

Are you or your loved ones suffering from glioma?

You may be eligible to participate in a glioma clinical trial.

Are you or your loved ones suffering from glioma? You may be eligible to participate in a glioma clinical trial.

Recruiting

Male & Female

18 +

years old

The primary objective of this phase II trial is to determine the efficacy and safety of ONC201, an oral small molecule imipridone DRD2 antagonist, in adult subjects with recurrent high-grade glioma. This study will test the research hypothesis that histone H3 K27M mutation sensitizes to oral administration of ONC201 in gliomas.

Where you'll go

Selected location

New York University School of Medicine

New York University School of Medicine Change

550 1st Avenue, New York, NY, USA 10016

Amy Patel, RN 212-731-6267

Get directions | Learn more

Available locations
Levine Cancer Institute

Levine Cancer Institute

Recruiting 1021 Morehead Medical Drive, Charlotte, NC, USA 28204

M D Anderson Cancer Center

M D Anderson Cancer Center

Recruiting 1515 Holcombe Boulevard, Houston, TX, USA 77030

Interested in participating?

Selected location

New York University School of Medicine

550 1st Avenue, New York, NY, USA 10016

Amy Patel, RN 212-731-6267


By clicking the button, you agree to the Terms and Privacy Policy.

Sign up now